Media

Oncopeptides publishes Q1 report 2025

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Intervacc – Interim report January – March 2025

Oncopeptides – Invitation to presentation of the Q1 report 2025

Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Vicore Pharma – Interim Report January – March 2025

Intervacc’s distribution partner Dechra launches Strangvac in Finland

Pulmonx Reports First Quarter 2025 Financial Results

Oncopeptides publishes the 2024 Annual Report